Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA – Research Report) and HealthStream (HSTM – Research Report).
Iovance Biotherapeutics (IOVA)
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Iovance Biotherapeutics, with a price target of $25.00. The company’s shares closed last Friday at $9.15.
According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Iovance Biotherapeutics with a $23.67 average price target, which is a 145.3% upside from current levels. In a report issued on February 8, Mizuho Securities also maintained a Buy rating on the stock with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
HealthStream (HSTM)
JMP Securities analyst Constantine Davides maintained a Hold rating on HealthStream today. The company’s shares closed last Friday at $27.57, close to its 52-week high of $27.85.
According to TipRanks.com, Davides has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on HealthStream is a Moderate Buy with an average price target of $32.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IOVA:
- Iovance (NASDAQ:IOVA): FDA Approves Cell Therapy, Stock Gains
- Iovance Biotherapeutics jumps 19% following conference call regarding Amtagvi
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance says Amtagvi black box label ‘looks pretty good’
- Iovance ‘extremely pleased’ with results of Amtagvi trial
